Industry News
Biotechnology Industry News
Merck & Co. is spending $9.2…
Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & Johnson last year.
Bristol Myers Squibb and Johnson…
Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.
Applied Therapeutics’ lack of…
Applied Therapeutics’ lack of progress on govorestat as well as the potential costs to come have led analysts to question whether the biotech will ever be able to get the drug to market.
Neuro biotech Ovid Therapeutics’…
Neuro biotech Ovid Therapeutics' C-suite is metamorphosing, with co-founder and longtime CEO Jeremy Levin, Ph.D., set to give up the reins. Levin will step down Jan. 1 to make room for Meg Alexander, who will become Ovid’s
European life sciences investor…
European life sciences investor Medicxi has raised 500 million euros (about $581.6 million) to go directly toward innovative biotechs.
Signed, sealed and delivered,…
Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, capping a whirlwind two weeks in which rival pharma Novo Nordisk attempted to swoop in and snatch the
Century Therapeutics, Candel…
Century Therapeutics, Candel Therapeutics and MacroGenics have all used their third-quarter earnings releases to disclose how they’re fine-tuning their clinical pipelines to conserve cash.
Third Arc Bio will use Adagene’s…
Third Arc Bio will use Adagene’s precision antibody masking platform—dubbed Safebody—to create new CD3 T-cell engagers against tumor-associated antigens.
Mersana Therapeutics’ decision…
Mersana Therapeutics' decision earlier this year to go all-in on its antibody-drug conjugate Emi-Le appears to have paid off.
Zealand is pausing development on…
Zealand is pausing development on its dual GLP-1/GLP-2 agonist, known as dapiglutide, as it strives to focus its time and money on “programs with the greatest potential for clinical differentiation and long-term value creation,” the
Korro Bio delivered a double…
Korro Bio delivered a double whammy of bad news, reporting lackluster data on its lead candidate and a pause to its partnership with Novo Nordisk. The biotech, which suffered a 79% stock drop in the
A phase 3 trial of Novartis’…
A phase 3 trial of Novartis’ next-generation malaria treatment has met its primary endpoint, positioning the drugmaker to seek approval of a therapy with the potential to kill drug-resistant parasites.
After forming from a merger hashed…
After forming from a merger hashed out over plates of tacos about a year ago, nChroma Bio is laying off staff and deprioritizing the research spearheaded by one of its founding companies.
In a highly anticipated article,…
In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory pathway that could trigger a seismic shift in how bespoke gene editing therapies are developed and approved.
AbbVie is ending an 11-year…
AbbVie is ending an 11-year agreement with Alphabet’s Calico Labs, according to an internal email obtained by Stat.
Who would have predicted that one…
Who would have predicted that one of the hottest trends for beleaguered biotechs in 2025 would be to rebrand as a crypto company?
One in four safety-related…
One in four safety-related failures are due to central nervous system (CNS) toxicity.
Alkermes has reported another…
Alkermes has reported another phase 2 win for its narcolepsy drug candidate, succeeding where Takeda failed to maintain its hopes of being first to market in the indication.
Bayer has cleared out four cancer…
Bayer has cleared out four cancer candidates from its early-stage pipeline, including a STAT3 inhibitor acquired as part of its buyout of Vividion Therapeutics.
A quarter of Metagenomi’s…
A quarter of Metagenomi’s employees, including the company’s CEO, are set to lose their jobs after the gene editing biotech decided to focus resources on its preclinical hemophilia A program.